XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Revenues
9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
REVENUES
REVENUES
Product Revenues
The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2016 and 2015:
 
Three months ended September 30,
 
Nine months ended September 30,
 
2016
 
2015
 
2016
 
2015
Products:
 
 
 
 
 
 
 
Acetadote
$
1,807,495

 
$
2,065,081

 
$
5,532,893

 
$
6,386,767

Omeclamox-Pak
752,808

 
691,120

 
2,154,596

 
2,393,495

Kristalose
3,671,397

 
3,939,294

 
10,915,276

 
12,160,037

Vaprisol
496,279

 
670,621

 
1,286,126

 
2,199,645

Caldolor
1,357,289

 
352,343

 
3,060,441

 
2,007,076

Ethyol
519,400

 

 
519,400

 

Other
187,085

 
166,589

 
475,388

 
334,543

Total net revenues
$
8,791,753

 
$
7,885,048

 
$
23,944,120

 
$
25,481,563


Cumberland supplies Perrigo Company ("Perrigo") with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $1.2 million and $1.1 million for the third quarter of 2016 and 2015 and $3.5 million and $3.3 million on a year-to-date basis as of September 30, 2016 and 2015, respectively.
Other Revenues
The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements. During the nine months ended September 30, 2016, the Company recognized $200,000 in milestone payments associated with these international agreements.